CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 289 enrolled
Drug / intervention
Rocuronium Bromide 10 MG/ML +1 moredrug
Likely dose
Rocuronium Bromide 10 MG/MLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06102915
NCT06102915N/ACompleted
CompareCT.gov

Rocuronium vs Cis-atracurium: Do Rocuronium Still 'ROCKS' In Coronary Artery Bypass Grafting

Institut Jantung Negara·observational·Posted Oct 26, 2023·Updated Nov 28, 2023

In Brief

An observational study evaluating Rocuronium Bromide 10 MG/ML and Nimbex 10 MG in 5 ML Injection for Neuromuscular Blockade and 5 related conditions. Completed, enrolled 289 participants across 1 site.

Detailed Summary

The current trend in most cardiac surgeries was to use rocuronium as it provides faster recovery in train-of-four ratio compared to other aminosteroid non-depolarising neuromuscular blocker. However, as most cardiac centres' standard of care does not perform any neuromuscular monitoring nor antagonism of neuromuscular blockade effect, residual neuromuscular blockade could potentially be the key to delayed extubation. As such, Cis-atracurium's organ-independent Hofmann elimination could be in favour.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNeuromuscular Blockade, Postoperative Pulmonary Atelectasis, Postoperative Pulmonary Complication, Coronary Artery Disease, Coronary Artery Bypass Grafting, Hypothermic Cardiopulmonary Bypass
CountriesMalaysia
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedOct 26, 2023
Enrollment StartAug 1, 2023
Primary CompletionNov 23, 2023
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 2.7 years ago

Interventions

Rocuronium Bromide 10 MG/MLdrug

Comparative

Nimbex 10 MG in 5 ML Injectiondrug

Comparative